Mesothelioma.com Resources for Patients and their Families

Mesothelioma Doctors

Nicholas J. Vogelzang, M.D.

Dr. Vogelzang
Las Vegas, NV

Dr. Nicholas J. Vogelzang

Medical Oncologist

Comprehensive Cancer Centers of Nevada

Central Valley Treatment Center
3730 S. Eastern Avenue
Las Vegas, NV 89169
(702) 952-3400

University of Illinois, Chicago, IL - 1974

Rush Presbyterian St. Luke’s Medical Center, Chicago, IL

University of Minnesota, Minneapolis, MN

Dr. Nicholas J. Vogelzang is a medical oncologist with the Comprehensive Cancer Centers of Nevada who currently serves as medical director for the US Oncology Research Executive Committee and associate chair for the Genitourinary and Developmental Therapeutics Programs. Prior to joining the staff of the Comprehensive Cancer Centers of Nevada in 2009, Dr. Vogelzang was director of the Nevada Cancer Institute (2004-2009) and professor and director of the University of Chicago Cancer Research Center (1999-2003).

Educational Background

Dr. Vogelzang attended medical school at the University of Illinois in Chicago where he earned his medical degree in 1974. He then went on to pursue an internship and residency in internal medicine at Rush Presbyterian St. Luke’s Medical Center also located in Chicago. Upon completion of his residency, Dr. Vogelzang relocated to Minneapolis, Minnesota where he completed a fellowship in medical oncology at the University of Minnesota.

Clinical and Laboratory Research

Board-certified in internal medicine and medical oncology, Dr. Vogelzang’s clinical specialties include mesothelioma and genitourinary malignancies—prostate, kidney, bladder, and testicular cancers. A dedicated researcher, Dr. Vogelzang has led and continues to lead groundbreaking clinical trials aimed at identifying new therapies and treatment approaches for cancer patients. In 2002, he served as director of the pemetrexed (Alimta®) trial—the largest phase II trial to date for mesothelioma. The results of this trial—which showed pemetrexed, when used in combination with cisplatin (a common chemotherapy agent), achieved tumor shrinkage in 41% of patients vs. only 17% of patients administered cisplatin alone—led to the FDA’s approval of pemetrexed in 2004 for the treatment of patients with malignant pleural mesothelioma. At the present time, Dr. Vogelzang is investigating new therapies for metastatic kidney cancer, prostate cancer, and metastatic bladder cancer.

Additional Work

Dr. Vogelzang is a noted lecturer who has authored/coauthored over 400 journal articles, in addition to numerous book chapters and abstracts. He is a member of several professional organizations, including, but not limited to, the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the American College of Physicians (ACP), the International Association for the Study of Lung Cancer (IASLC), the European Society for Medical Oncology (ESMO), and the Mesothelioma Foundation. Among his many accolades, he has been awarded the Gold Certificate of Excellence by the National Cancer Institute and has been named “Top Doctor” by U.S. News & World Report. Dr. Vogelzang is highly-regarded by his peers and patients alike in the cancer community for his clinical practice, research efforts, and career-long dedication to advancing cancer therapies and treatments. His work and progress in cancer research has been featured via well-respected national multimedia outlets such as 60 Minutes, The New England Journal of Medicine, Nature, USA Today, and The New York Times.

Publications

Dr. Vogelzang’s published articles:
http://www.ncbi.nlm.nih.gov/pubmed?term=Vogelzang+NJ%5Bauthor%5D&cmd=detailssearch

Sources
Mesothelioma Doctors by State
  • Top Doctors and Clinics
  • Clinical Trial Information
  • Delivered within 24 hrs

Yes   No

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: